Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nanrilkefusp alfa + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- SOTIO Biotech AG
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
**Nanrilkefusp alfa + pembrolizumab** is an investigational combination therapy for advanced solid tumors. Nanrilkefusp alfa is a recombinant fusion protein that acts as an interleukin-15 receptor βγ (IL-15Rβγ) superagonist, designed to selectively stimulate cytotoxic natural killer (NK) and CD8+ T cells and promote an anti-tumor immune response. Pembrolizumab is a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), enhancing T cell anti-tumor activity by blocking inhibitory signaling. This combination aims to boost both innate and adaptive immune responses for synergistic anti-tumor effects. Development of this combination for solid tumors was discontinued due to insufficient efficacy in clinical trials, but data suggest a favorable safety profile and evidence of immune activation in some checkpoint-resistant/refractory patients[1][4][9][10].
- Other names
- nanrilSOT101SOT-101SOT 101pembrolizumabanti-PD-1 antibodyanti-PD1 antibodyanti-PD 1 antibody
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on nanrilkefusp alfa + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nanrilkefusp alfa + pembrolizumab.